Cargando…

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of viremia. This open-label, multiple ascending dose s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colston, Elizabeth, Grasela, Dennis, Gardiner, David, Bucy, R. Pat, Vakkalagadda, Blisse, Korman, Alan J., Lowy, Israel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991705/ https://www.ncbi.nlm.nih.gov/pubmed/29879143 http://dx.doi.org/10.1371/journal.pone.0198158

Ejemplares similares

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro
por: Rosskopf, Sandra, et al.
Publicado: (2019)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
por: Leung, Anna M., et al.
Publicado: (2014)

Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
por: Venditti, Olga, et al.
Publicado: (2015)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
por: Gardiner, David, et al.
Publicado: (2013)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
por: Tarhini, Ahmad
Publicado: (2013)

Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry
por: Franco, Antonio, et al.
Publicado: (2023)

Elite and viremic HIV-1 controllers in West Africa
por: N’takpé, Jean Baptiste, et al.
Publicado: (2022)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

2081: Phenotypic characterization of the CD4+ T-cell response during anti-CTLA4 therapy with ipilimumab in melanoma patients
por: Sherani, Farha, et al.
Publicado: (2018)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Hasanov, Merve, et al.
Publicado: (2021)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Ipilimumab
Publicado: (2012)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Low levels of anti-MPER antibodies are detectable in viremic HIV infected
por: Carrillo, J, et al.
Publicado: (2012)

Dengue transmission model by means of viremic adult immuno-competent mouse
por: Runtuwene, Lucky Ronald, et al.
Publicado: (2014)

Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers
por: Gonzalo-Gil, Elena, et al.
Publicado: (2017)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Sustained Viremic Control in HIV-Infected Patient: Case Report from Nepal
por: Khadka, Sundar, et al.
Publicado: (2018)

Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections
por: Sayad, Babak, et al.
Publicado: (2018)

ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques
por: Azar, Sasha R., et al.
Publicado: (2018)

Heart Transplant Using Hepatitis C-Seropositive and Viremic Organs in Seronegative Recipients
por: Zhu, Yuanjia, et al.
Publicado: (2020)

Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients
por: Axelrod, David A., et al.
Publicado: (2020)

Viremic dissemination of mouse hepatitis virus-JHM following intranasal inoculation of mice
por: Barthold, S. W., et al.
Publicado: (1992)

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
por: Czarnecka, Paulina, et al.
Publicado: (2022)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
por: Queirolo, Paola, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_at8dkcg5522ef5ru20uhd1v5nn